Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $1,050.00

Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price target raised by Guggenheim from $800.00 to $1,050.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also issued reports on PRAX. The Goldman Sachs Group reiterated a “buy” rating and issued a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Robert W. Baird boosted their price target on Praxis Precision Medicines from $514.00 to $568.00 and gave the stock an “outperform” rating in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $582.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, September 24th. Wells Fargo & Company dropped their price objective on Praxis Precision Medicines from $362.00 to $343.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $826.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $656.42.

Read Our Latest Stock Analysis on PRAX

Praxis Precision Medicines Price Performance

Shares of NASDAQ:PRAX opened at $305.19 on Monday. The company’s 50 day simple moving average is $287.32 and its 200 day simple moving average is $314.29. The stock has a market capitalization of $8.53 billion, a price-to-earnings ratio of -23.84 and a beta of 2.85. Praxis Precision Medicines has a 1 year low of $160.11 and a 1 year high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31. As a group, analysts anticipate that Praxis Precision Medicines will post -13.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PRAX. Algert Global LLC boosted its position in Praxis Precision Medicines by 4.5% during the 3rd quarter. Algert Global LLC now owns 18,268 shares of the company’s stock worth $5,320,000 after buying an additional 790 shares during the period. Allworth Financial LP grew its holdings in Praxis Precision Medicines by 217.9% during the 3rd quarter. Allworth Financial LP now owns 248 shares of the company’s stock worth $72,000 after acquiring an additional 170 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Praxis Precision Medicines during the 3rd quarter worth approximately $2,148,000. Bellevue Group AG grew its holdings in Praxis Precision Medicines by 261.5% during the 3rd quarter. Bellevue Group AG now owns 6,676 shares of the company’s stock worth $1,944,000 after acquiring an additional 4,829 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in Praxis Precision Medicines in the 3rd quarter valued at approximately $284,000. Institutional investors and hedge funds own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Further Reading

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.